Abstract
Subject Index
Abdominal cancer, 223–230
Ab-SPIO-labeled cells, 211–221
Active targeting of micrometastases, 291–306
Adenosine diphosphate (ADP)-ribosyltransferase 2, 211–221
Adenovirus breast cancer and, 59–74 expressing MDR1 shRNA, 344–350
Ad-shMDR1 infected tumors, 344–350
Affibody-based fluorescence contrast agents, 192–200
Alexa Fluor 750 fluorophores, 192–200
α-emitting radionuclides, 1–15
Angiogenesis, of tumors, 96–106
Annulus fibrosus, of intervertebral disk, 128–140
Antiproliferative effect, of ibuprofen, 233–236
Antitumor immunity, 141–150
Apoptotic bilabeled hMSCs, 278–289
Arginine-glycine-aspartic acid (RGD) dimer with tetra linkers, 21–28
Arterial plasma time-activity curves (TACs), 76–85
Arthritic joints, 278–289
Atomic absorption spectrometry (AAS), 211–221
Attenuation-emission misregisration, 256–266
Atypical epithelial breast hyperplasia, 233–236
Automated modular microfluidic platforms, 175–188
Background radioactivity, intestinal, 47–57
Batch-based microfluidic reactors, 175–188
β-emitting radionuclides, 1–15
Bilabeled mesenchymal stem cells (MSCs), 278–289
Biologic evaluation, of (R)- and (S)- enantiomers, 329–341
Biologic nanoparticles, 291–306
Bioluminescence imaging (BLI) of MDR1/Pgp reversal, 344–350 MRI and, for tumor monitoring, 163–171
Biomedical imaging, NPs for, 291–306
Blood brain barrier (BBB) gliosarcoma tumors and, 329–341 multiple sclerosis and, 268–276 NIR light penetrating, 237–252 NPs crossing of, 291–306
Brain tumor imaging, 329–341
Breast cancer HER2-targeted therapy for, 192–200 labeled adenoviruses in, 59–74 99MTc-(V)DMSA uptake, 233–236 NIRF camera system for, 223–230 SLN mapping and, 237–251
C2C12 myoblasts, 201–209
Cancer breast, labeled adenoviruses in, 59–74 HER2-targeted therapy for, 192–200 immunotherapy, 141–150 optical image-guided surgery, 223–230
Capsid labeling, of oncolytic adenoviruses, 59–74
Carbon-based nanoparticles, 291–306
Carcinoma. See Cancer
Cardiac grafts, 201–209
Cardiac PET-CT, 256–266 See also Positron emission tomography-computed tomography (PET-CT)
Cell transplantation myocardial infarction and, 201–209 for rheumatoid arthritis, 278–289
Central nervous system (CNS), monocyte infiltration of, 268–276
Centralized PET probe distribution, 175–188
Charge-coupled device (CCD) camera, 30–38
Chemotherapy, with temozolomide (TMZ), 40–45
Chromophore imaging, 251
Cine CT attenuation scan, 256–266
Click reaction, 329–341
Clinical translation of nanoparticles, 291–306 of NIRF imaging, 237–251
Coelenterazine, 344–350
Colorectal carcinoma, 223–230
Computed tomography (CT) of injured spinal cord, 108–115 quantitative accuracy of helical vs. cine, 256–266 See also Positron emission tomography-computed tomography (PET-CT)
Concentration-dependent fluorescence quenching, 237–251
Conditionally replicative adenoviruses (CRAds), 59–74
Continuous-flow microfluidics, 175–188
Contrast agents affibody-based fluorescence, 192–200 DiD, 278–289 endorem, 268–276 ferucarbotran, 278–289 for intervertebral disk imaging, 128–140 microbubble, 87–94 nano-sized ultrasound, 96–106 for NIR fluorescence-guided surgery, 237–251 for ultrasonic MI, 117–125
Contrast sensitivity enhancement, 87–94
CT attenuation scan, 256–266
Cy5-PLA conjugates, 153–160
Cyclotron targetry, for radionuclides, 1–15
Decentralized PET probe production, 175–188
Dendrimers, 291–306
Depth-of-interaction (DOI) correction, 311–318
Depth-sensitive imaging, 250–251
DiD contrast agent, 278–289
Diskectomy, 128–140
DNA vaccination, 141–150
Drug delivery system, of PNPs, 153–160
Echogenicity, of nano-sized UCAs, 96–106
Ectoenzyme, leukocyte cell-surface, 211–221
[18F]2-fluoro-2-deoxy-
[18F]FDG radiosynthesis, 175–188
[18F]FDG-PET CT and, 108–115 noninvasive imaging and, 76–85
Electron microscopy, 211–221
[11C]CO radiolabelling, 175–188
Endorem contrast agent, 268–276
Engraftment of stem cells, 201–209
Enhanced Permeability and Retention (EPR) effect, 96–106, 291–306
Enzymatic activity, 211–221
Epithelial hyperplasia, breast, 233–236
Experimental autoimmune encephalomyelitis (EAE), 268–276
Ferritin overexpression, 201–209
Ferucarbotran contrast agent, 278–289
Field of view (FOV), in PET, 311–318
Filtered broadband sources, of NIR fluorophores, 237–251
FLARE™ imaging system, 237–251
Flow cytometry, 211–221
FLT-PET imaging, 40–45
Fluobeam camera system, 223–230, 241
Fluorescence imaging (FLI), 128–140
Fluorescence lifetime imaging (FLIM), 237–251
Fluorescence-Assisted Resection and Exploration (FLARE™), 237–251
Fluorescent imaging of HER2 receptor expression, 192–200 of intervertebral disk, 128–140 of intestinal injury, 30–38
Fluorescent viral particles, 59–74
FM (styryl pyridinium) fluorophores, 128–140
68Ga-DOTATOC PET/CT, 352–358
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), 352–358
Gene therapy, 344–350
Genetic capsid labeling, 59–74
Glioblastoma multiforme (GBM), 40–45
Gliosarcoma brain tumor, 329–341
Gold-containing nanoparticles, 291–306
Helical CT attenuation scan, 256–266
Hepatic metastases, 352–358
HSV1-tk reporter imaging, 47–57
Human epidermal growth factor receptor 2 (HER2), 192–200
Human mesenchymal stem cells (hMSCs), 278–289
Human sodium iodide symporter (hNIS), 141–150
Hydrodynamic diameter (HD) ranges, 291–306
Ibuprofen, uptake of proliferation-seeking radiotracer and, 233–236
Image-derived input function (IDIF), hybrid, 76–85
Image-guided tumor resection invisible NIR light and, 237–251 NIRF camera system for, 223–230
Imaging markers. See Contrast agents
Imaging-guided TMZ chemotherapy, 40–45
Immunofluorescence, of Ab-SPIO-labeled cells, 211–221
Immunotherapy, 141–150
In vivo fluorescent imaging of HER2 receptor expression, 192–200 of intervertebral disk, 128–140 of intestinal injury, 30–38
In vivo scintigraphic imaging, 141–150
Indocyanine green (ICG) contrast agent, 237–251
Infiltrated monocytes, 268–276
Inflammatory sites, 211–221
Inorganic nanoparticles, 291–306
Integrated BLI-MRI, 163–171
Integrin αvβ3 expression, 21–28
Intervertebral disk, annulus fibrosus of, 128–140
Intestines injuries of, 30–38 radioactivity of, 47–57
Intraoperative NIRF camera system, 223–230
Intravenous injection of [18F] FDG, 76–85, 108–115 of fluorophores, 128–140, 237–252 of labeled monocytes, 268–276 of NPs, 291–306 of SPIO-conjugated antibodies, 211–221
Iron oxide nanoparticles, 295–296
Laser diodes, 237–251
Left ventricle TAC, 76–85
Leukocyte cell-surface ectoenzyme, 211–221
Ligand architecture, in ultrasound MI, 117–125
Light-emitting diodes (LEDs), 237–251
Lines-of-response (LORs), 311–318
Liposomes, 291–306
Liver time-activity curves within, 76–85 tumors of, 352–358
Low back surgery, 128–140
Low-mechanical index imaging, 123
Lymph nodes, PET-CT assessment, 319–327
Lymphatic biodistribution, of polylactide NPs, 153–160
Magnetic resonance imaging (MRI) BLI and, 163–171 of cell surface enzymatic activity, 211–221 of intervertebral disk, 128–140 of transplanted stem cells, 201–209 of USPIO-labeled monocytes, 268–276 of viable/nonviable MSCs, 278–289
Magnetoelectroporation (MEP) labeling, 268–276
Mammary carcinoma, 59–74
Mammary uptake, of 99MTc-(V)DMSA, 233–236
Mathematical modeling, with optical imaging, 192–200
mCherry-CRAd imaging tag, 59–74
MDR1/Pgp reversal, 344–350
Mesenchymal stem cells (MSCs), 278–289
Metal oxide nanoparticles, 295–296
Methlylene blue (MB) contrast agent, 237–251
MET-PET imaging, 40–45
Microbubble contrast agents (MCAs), 87–94, 117–125
Microfluidics-based PET radiochemistry, 175–188
MicroPET imaging arterial blood input function and, 76–85 for brain tumor imaging, 329–341 intestinal background radioactivity and, 47–57
Microscopy, electron, 211–221
Mini-FLARE™ imaging system, 241–242
Molecular dots, 291–306
Molecular imaging nanoparticles (NPs) for, 291–306 sensitivity improvements, 87–94
Molecular tagging of graft cells, 201–209
Monocytes, USPIO-labeled, 268–276
Monodispersity, of contrast agents, 117–125
Monte Carlo simulation, 108–115
Mouse tumor monitoring, with integrated BLI-MRI, 163–171
MR relaxometry, 211–221
mRFP1-CRAd imaging tag, 59–74
Multidrug resistance 1 (MDR1) gene, 344–350
Multimodal imaging, with MRI and BLI, 163–171
Multimodal SUV, 319–327
Multiple sclerosis (MS), 268–276
Myocardial infarction, 201–209
Myocardial perfusion, 256–266
Nanoparticles (NPs) for biomedical imaging, 291–306 lymphatic biodistribution of, 153–160 as UCAs, 96–106
Nano-sized ultrasound contrast agents, 96–106
Nanowires, 291–306
National Nanotechnology Initiative (NNI), 291–306
Near-infrared fluorescence (NIRF) camera system, 223–230
Near-infrared fluorescence (NIRF) imaging angiography, 248 development and clinical translation, 237–251 of HER2 receptor expression, 192–200 of integrin αvβ3 expression, 21–28 novel technique for intestinal injury, 30–38
99MTc-(V)DMSA radiotracer, 233–236
NIR fluorophores, 237–251 Noninvasive imaging of arterial blood input function, 76–85 of cell surface proteins, 211–221 of HER2 expression in vivo, 192–200 of integrin αvβ3 expression, 21–28 of intestinal injury, 30–38 of oncolytic adenoviruses, 59–74 of stem cells transplanted into heart, 201–209
Nonviable mesenchymal stem cells, 278–289
Nuclides, 1–15
Nulytely laxative agent, 47–57
Oncolytic adenoviruses, 59–74
1H-[1,2,3]triazole group, 329–341
131I + hNIS combination therapy, 141–150
Optical imaging integrated BLI-MRI and, 163–171 of integrin αvβ3 expression, 21–28 intraoperative NIRF camera for, 223–230 with mathematical modeling, 192–200 of viable/nonviable MSCs, 278–289
Optical properties, for NIRF contrast agents, 237–251
Organic nanoparticles, 291–306
Orthotopic breast cancer, 59–74
Partial volume correction (PVC), 319–327
Peptamen laxative agent, 47–57
Perfusion imaging, 87–94
PET. See Positron emission tomography (PET)
PET-CT. See Positron emission tomography-computed tomography (PET-CT)
P-glycoprotein (Pgp)-mediated drug resistance, 344–350
Physical decay characteristics of radionuclides, 1–15
Physiochemical properties for NIRF contrast agents, 237–251
Polylactide (PLA) nanoparticles, 153–160
Polymeric nanoparticles (PNPs), 153–160, 291–306
Positron emission tomography (PET) with [18F] FDG, 76–85 HSV1-tk reporter, 47–57 of injured spinal cord, 108–115 of intervertebral disk, 128–140 microfluidics for, 175–188 probe distribution models, 175–188 radionuclides, 1–15 small-animal scanner, 311–318
Positron emission tomography-computed tomography (PET-CT) cardiac, shifted helical CT and, 256–266 of injured spinal cord, 108–115 for lymph node assessment, 319–327 monitoring GEP-NETs, 352–358
Proliferation-seeking radiotracer 99MTc-(V)DMSA, 233–236
Quantitative analysis of HER2 receptor expression in vivo, 192–200 of lymph nodes with PET-CT, 319–327
Quantitative improvement, 256–266
Quantitative magnetic resonance imaging, 211–221
Quantum dots (QDs), 291–306
R2 relaxometry, 211–221
Radial resolution loss, 311–318
Radiation force-enhanced targeting, 124
Radioiodine (131I) therapy, 141–150
Radioisotope delivery, 175–188
Radiolabeling amino acids, 329–341 for PET, 175–188 trastuzumab, 192–200
Radionucleoside imaging, 47–57
Radiopharmaceuticals, 1–15
Radiosynthesis of (R)- and (S)-[18F]4, 329–341
Radiotracer dosages, 237–251
Real-time molecular imaging, 122–123
Red fluorescent reporters, 59–74
Relaxometry, MR, 211–221
Renal clearance, of NPs, 291–306
(R)-enantiomer of [18F]4, 329–341
Renilla luciferase (Rluc) gene, 344–350
Resection of tumors, 223–230
RGD (arginine-glycine-aspartic acid) dimeric probes, 21–28
Rheumatoid arthritis (RA), 278–289
Ribonucleic acid interference (RNAi), 344–350
(S)-[18F]4 amino acid, 329–341
Salting-out method, 96–106
Scintigraphic imaging, 141–150
Scintimammography, 233–236
Semiautomatic algorithm for lymph node analysis, 319–327
(S)-enantiomer of [18F]4, 329–341
Sensitivity enhancement, in ultrasound MI, 87–94
Sentinel lymph node (SLN) mapping, 237–251
Serial imaging, 108–115
Severe epithelial breast hyperplasia, 233–236
Shifted helical CT, 256–266
Silica nanoparticles, 291–306
Simulation partial-volume compensation (PVC), 108–115
Sinerem contrast agent, 268–276
Single dose on demand PET probe production, 175–188
Single-photon emission computed tomography (SPECT) radionuclides, 1–15 See also Computed tomography (CT)
Size, of nano-sized UCAs, 96–106
Size distribution, of MCAs, 87–94, 117–125
Small hairpin ribonucleic acid (shRNA), 344–350
Small-animal imaging integrated BLI-MRI for, 163–171 PET scanners, for spinal cord, 108–115
Somatostatin receptor radionuclide therapy (SRRT), 352–358
Spatial sampling density, 311–318
Spectral imaging of intervertebral disk, 128–140 of oncolytic adenoviruses, 59–74
Spectrometry, atomic absorption, 211–221
Spillover effect, 108–115
Spinal cord injury, 108–115
Standardized uptake value (SUV) of hepatic metastases, 352–358 of lymph nodes, 319–327
Stem cells transplantation into heart, 201–209 viable/nonviable MSC, 278–289
Styryl pyridinium (FM) fluorophores, 128–140
Submicron contrast agents, in ultrasound MI, 124
Superparamagnetic iron oxide (SPIO) labeled cells, MRI of, 211–221 monocytes labeled with, 268–276
Supravist contrast agent, 268–276
Surgical oncology, 223–230
Suspicious lymph nodes, 319–327
T cells, 211–221
Targeted imaging, 87–94, 117–125 See also Contrast agents
Technetium 99m-pentavealent dimercaptosuccinic acid (99MTc-(V)DMSA), 233–236
Temozolomide (TMZ) chemotherapy, 40–45
Tetra (ethylene glycol) linkers, 21–28
Therapeutic agents, 1–15
Therapeutic cell transplantation, 278–289
Therapy monitoring, of hepatic metastases, 352–358
Time-activity curves (TACs), 76–85
Toxicity, of NPs, 291–306
Transgenic grafts, 201–209
Transplantation cell, for rheumatoid arthritis, 278–289 of stem cells into heart, 201–209
Tumor inhibition, 141–150
Tumor metastases, 153–160
Tumors brain, microPET of, 329–341 camera-guided resection, 223–230 gastroenteropancreatic neuroendocrine, 352–358 HER2 receptor expression in, 192–200 imaging CRAd replication in, 59–74 integrated imaging of, 163–171 MRI of enzymatic activity characterizing, 211–221 NIRF margin detection, 248 PET-CT assessment of, 319–327 radiotracer 99MTc-(V)DMSA, 233–236 RGD dimer with tetra linkers targeting of, 21–28 targeting with NPs, 291–306 ultrasound imaging of, 96–106
Ultrasmall superparamagnetic iron oxide (USPIO), 268–276
Ultrasonography advances in, 117–125 tailoring size distribution, 87–94
Ultrasound contrast agents (UCAs) advances in, 117–125 for tumor imaging, 96–106 See also Contrast agents
Unconventional nuclides, 1–15
Vaccine-based immunotherapy, 141–150
Venous blood sample, for hybrid IDIF, 76–85
Viable mesenchymal stem cells, 278–289
Virotherapy, 59–74
Volumetric imaging, in ultrasound MI, 123–124
Volumetric therapy monitoring, 352–358
Xenografts, 192–200
Zwitterionic nanoparticles, 291–306
Author Index
Adam, Gerhard, 211
Adams, Susan J., 329
Ahn, Byeong-Cheol, 344
Antsaklis, Aris, 233
Archontaki, Aikaterini, 233
Backes, Heiko, 40
Bae, Seon-ae, 344
Baehner, Rick, 278
Baird, Andrew, 30
Balcerak, Philipp, 211
Bannas, Peter, 211
Bansal, Vishal, 30
Barnhardt, Nicole E., 128
Berchtenbreiter, Christian, 319
Blasberg, Ronald G., 47
Blezer, Erwin L.A., 268
Boddington, Sophie, 278
Boppart, Stephen A., 153
Borovjagin, Anton V., 59
Brader, Peter, 47
Brunn, Anna, 40
Bulte, Jeff W.M., 268
Bundschuh, Ralph A., 319
Burghaus, Lothar, 40
Cai, Shangde, 47
Chaney, Eric J., 153
Chen, Xiaoyuan, 21
Cheng, Jianjun, 153
Chernomordik, Victor, 192
Choi, Dae Han, 141
Choi, Hak Soo, 237, 291
Choi, Yun, 141
Chung, June Key, 141
Coimbra, Raul, 30
Costantini, Todd W., 30
Curiel, David T., 59
Daldrup-Link, Heike, 278
Dayton, Paul A., 87, 117
De Vries, Helga E., 268
Deem, Jennifer, 201
Delso, Gaspar, 319
Demos, Stavros, 278
Dijkstra, Christine D., 268
Dijkstra, Jouke, 223
Dimitrakakis, Konstantinos, 233
Dinges, Julia, 319
Eliceiri, Brian P., 30
Engberink, Raoul D. Oude, 268
Essler, Markus, 319
Fish, Kenneth M., 128
Fothiadaki, Athina, 233
Frangioni, John V., 128, 237, 291
Galldiks, Norbert, 40
Gandjbakhche, Amir, 192
Gessner, Ryan, 87, 117
Gibbs-Strauss, Summer L., 128
Gioux, Sylvain, 237
Gould, K. Lance, 256
Graumann, Oliver, 211
Green, Michael V., 311
Griffin, Elizabeth A., 329
Grotenhuis, J. Andre, 108
Ha, Jeoung-Hee, 344
Haag, Friedrich, 211
Haishi, Tomoyuki, 163
Hartmann, Holger, 352
Hassan, Moinuddin, 192
Hehir, Cristina A. Tan, 128
Heiss, Wolf-Dieter, 40
Henning, Tobias D., 278
Hohberg, Melanie, 319
Hohenberg, Heinrich, 211
Holland, Jason P., 1
Hricak, Hedvig, 47
Hurtado, Andres, 108
Hutterman, Merlijn, 223
Inoue, Yusuke, 163
Ittrich, Harald, 211
Jacobs, Andreas Hans, 40
Jeon, Yong Hyun, 141, 344
Johnson, Nils P., 256
Jones, Lynne A., 329
Kaijzel, Eric L., 223
Karianos, Theodore, 233
Kaul, Michael Gerhard, 211
Keijzer, Rob, 223
Kim, Chul Woo, 141
Kiryu, Shigeru, 163
Ko, Jinkyung, 141
Koch-Nolte, Friedrich, 211
Kornak, John, 278
Kracht, Lutz W., 40
Krug, Christian, 278
Kuppen, Peter J.K., 223
Lee, Hsiaoju, 329
Lee, Jaetae, 344
Lee, Sang Bong, 192
Lee, Sang-Woo, 344
Lee, Yong Jin, 344
Lee, You La, 344
Lewandowski, John, 96
Lewis, Jason S., 1
Lin, Wei-Yu, 175
Lipman, Neil S., 47
Liu, Kan, 175
Liu, Shuang, 21
Liu, Shuanglong, 21
Liu, Zhaofei, 21
Loomis, William H., 30
Löwik, Clemens W.G.M., 223
Luboldt, Hans-Joachim, 352
Luboldt, Wolfgang, 352
MacDougall, Mary J., 59
Mach, Robert H., 329
Marinopoulos, Spyridon, 233
Mariss, Jan, 319
Martínez-Möller, Axel, 319
Masterman-Smith, Michael, 175
Masutani, Yoshitaka, 163
McConathy, Jonathan, 329
McNally, Lacey R., 59
Meier, Reinhardt, 278
Mieog, J. Sven D., 223
Miles, Iman, 87
Murry, Charles E., 201
Nasr, Khaled A., 128
Naumova, Anna V., 201
Nekolla, Stephan G., 319
Niu, Gang, 21
Ohtomo, Kuni, 163
Ostrow, Harold G., 311
Oudega, Martin, 108
Paik, Jin Ho, 141
Pan, Tinsu, 256
Papantoniou, Vassilios, 233
Peldschus, Kersten, 211
Peterson, Carrie Y., 30
Peterson, Todd E., 76
Pomper, Martin G., 108, 311
Putnam, James G., 30
Que, Ivo, 223
Rahiem, Sahar T., 108
Reinecke, Hans, 201
Ruggiero, Alessandro, 47
Schulz, Dominik, 319
Schwaiger, Markus, 319
Seidel, Jurgen, 108, 311
Serganova, Inna, 47
Sharifi, Sheida, 278
Shen, Clifton Kwang-Fu, 175
Shockley, Stephany E., 329
Siclovan, Tiberiu M., 128
Sotiropoulou, Evangelia, 233
Sotiropoulou, Maria, 233
Streeter, Jason E., 87
Sutton, Elizabeth Jane, 278
Syrgiannis, Konstantinos, 233
Tang, Li, 153
Tantawy, Mohammed Noor, 76
Tewarie, Rishi D.S. Nandoe, 108
Tojo, Arinobu, 163
Tong, Rong, 153
Tsaroucha, Angeliki, 233
Tsiouris, Spyridon, 233
Tsui, Benjamin M. W., 108
Ullrich, Roland T., 40
Vahrmeijer, Alexander L., 223
Valsamaki, Pipitsa, 233
van de Velde, Cornelis J.H., 223
van der Pol, Susanne M.A., 268
van der Toorn, Annette, 268
van der Vorst, Joost R., 223
van Hooff, Maurits Drijfhout, 223
Viergever, Max. A., 268
Vooght, Carrie, 128
Walczak, Pjotr, 268
Wang, Fan, 21
Wang, Minghui, 59
Wang, Ming-Wei, 175
Watanabe, Makoto, 163
Wheatley, Margaret A., 96
Wiedermann, Bärbel, 352
Williamson, Matthew J., 1
Wolf, Paul, 30
Yarnykh, Vasily, 201
Yoon, Ghil-Suk, 344
Yu, Jianhua, 108
Yuan, Chun, 201
Zanzonico, Pat, 47
Zhao, Shoujun, 278
Zhou, Dong, 329
Ziegler, Sibylle I., 319
Zielinski, Rafal, 192
Zinn, Kurt R., 59
Zöphel, Klaus, 352